Journals / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 5

Possible relationship between the resistin gene C-420G polymorphism and colorectal cancer in a Turkish population

Pages
392–6
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our study is important because to our knowledge, it is the first one to be conducted in a Turkish population to date, but we believe that more patients and controls are needed to obtain statistically significant results. the in

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: In recent years, with improvements in genotyping, a possible relationship between obesity- related gene polymorphisms and colorectal cancer (CRC) has been studied.
📊
Key Findings & Data:The promoter region C-420G ofresistin gene is believed to have an important role in the development of malignancy.
💡
Conclusion & Impact:Our study is important because to our knowledge, it is the first one to be conducted in a Turkish population to date, but we believe that more patients and controls are needed to obtain statistically significant results. the in
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: In recent years, with improvements in genotyping, a possible relationship between obesity- related gene polymorphisms and colorectal cancer (CRC) has been studied. The promoter region C-420G ofresistin gene is believed to have an important role in the development of malignancy. We prospectively evaluated the possible effect of the resistin C-420G polymorphism on the risk and prognosis of CRC. Materials and Methods: One hundred twenty-three patients with CRC and 79 healthy individuals were included in the study. Blood samples were genotyped, and the relationship between the resistin C-420G polymorphism and demographic characteristics and tumor features was evaluated. Results: No statistically significant difference was found in genotype distribution between the patient and control groups and among patients in the means of gender, biochemical findings, and tumor characteristics (p>0.05). Conclusion: The relationship between the C-420G polymorphism and various diseases has been evaluatedmany studies to date. With the increased importance of obesity in etiopathogenesis, studies have focused on CRC. According to our results, the GG genotype may be associated with a decreased CRC risk. Our study is important because to our knowledge, it is the first one to be conducted in a Turkish population to date, but we believe that more patients and controls are needed to obtain statistically significant results. the in

🔖

Cite This Article

DÜZKÖYLÜ, Y., ARIKAN, S., TURAN, S., YAYLIM, İ., DOĞAN, M. B., SARI, S., ERSÖZ, F., ZEYBEK, Ş. Ü. (2015). Possible relationship between the resistin gene C-420G polymorphism and colorectal cancer in a Turkish population. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 5, 392–6. https://ajindex.com/articles/409448

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Winawer SJ. The multidisciplinary management of gastrointesti- nal cancer. Colorectal cancer screening. Best Pract Res Clin Gas- troenterol 2007; 21: 1031-48.
  2. Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. BMJ 2000; 7264: 805-8.
  3. Carvajal-Carmona LG, Spain S, Kerr D, et al. Common variation at the adiponectin locus is not associated with colorectal cancer risk in the UK. Hum Mol Genet 2009; 18: 1889-92.
  4. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat ac- cumulation and plasma adiponectin withcolorectal adenoma: Evidence for participation of insulin resistance. Clin Cancer Res 2005; 15; 11: 3642-6.
  5. Ma Y, Wang F, Zhang P, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One 2013; 8: e53916. 6. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772–83. 7. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in hu- man macrophages and directly regulated by PPAR gamma acti- vators. Biochem Biophys Res Commun 2003; 300: 472-6. 8. Yura S, Sagawa N, Itoh H, et al. Resistin is expressed in the human placenta. J Clin Endocrinol Metab 2003; 88: 1394-7. 9. Minn AH, Patterson NB, Pack S, et al. Resistin is expressed in pan- creatic islets. Biochem Biophys Res Commun 2003; 310: 641-5. 10. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellu- lar signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335-40. 11. Engert JC, Vohl, MC, Williams SM, et al. 5’ Flanking variants of resis- tin are associated with obesity. Diabetes 2002; 51: 1629-34. 12. Osawa H, Onuma H, Murakami A, et al. Systematic search for single nucleotide polymorphisms in the resistin gene. Diabetes 2002; 51: 863-6. 13. Chung SS, Choi HH, Kim KW, Cho YM, Lee HK, Park KS. Regulation of human resistin gene expression in cellsystems: an important role of stimulatory protein 1 interactionwith a common promoter polymorphic site. Diabetologia 2005; 48: 1150-8. 14. Cho YM, Youn BS, Chung SS, et al. Common genetic polymor- phisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 2004; 47: 559-65. 15. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003; 52: 1611-8